“Perfect Storm” Flattens Perrigo Consumer Sales, Cuts Income 57%
This article was originally published in The Tan Sheet
Executive Summary
The harsh winter, weak cough/cold season and poor retail environment created “a difficult quarter for our consumer business,” which reported flat sales, says Perrigo CEO Joseph Papa. The firm also reported a continued delay in re-launching generic versions of the Mucinex expectorant line.
You may also be interested in...
With Generic Mucinex Delayed, Perrigo Will Need Alternatives To Drive Sales Growth
Perrigo hopes to ship store-brand Mucinex expectorant products in time for the next cough and cold season, but analysts are skeptical with several targets for the launch missed already. However, the firm can drive growth through mergers and acquisitions and Rx-to-OTC growth opportunities.
With Generic Mucinex Delayed, Perrigo Will Need Alternatives To Drive Sales Growth
Perrigo hopes to ship store-brand Mucinex expectorant products in time for the next cough and cold season, but analysts are skeptical with several targets for the launch missed already. However, the firm can drive growth through mergers and acquisitions and Rx-to-OTC growth opportunities.
Perrigo Consumer Product Growth Slows While Overall Sales Climb
The private labeler reported $53 million in new product sales for its Q2, but says the return to stores of branded OTCs, which had been recalled due to manufacturing problems, continues to diminish its consumer health product sales growth.